University of South Florida

Digital Commons @ University of South Florida
Graduate Theses and Dissertations

Graduate School

June 2021

CircREV1 Expression in Triple-Negative Breast Cancer
Meagan P. Horton
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the Cell Biology Commons, and the Molecular Biology Commons

Scholar Commons Citation
Horton, Meagan P., "CircREV1 Expression in Triple-Negative Breast Cancer" (2021). Graduate Theses and
Dissertations.
https://digitalcommons.usf.edu/etd/9133

This Thesis is brought to you for free and open access by the Graduate School at Digital Commons @ University of
South Florida. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized
administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

CircREV1 Expression in Triple-Negative Breast Cancer

by

Meagan P. Horton

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science
with a concentration in Cell and Molecular Biology
Department of Cell Biology, Microbiology, and Molecular Biology
College of Arts and Sciences
University of South Florida
Co-Major Professor: Margaret Park, Ph.D.
Co-Major Professor: Charles Chalfant, Ph.D.
Sandy Westerheide, Ph.D.
Florian Karreth, Ph.D.
Date of Approval:
June 7, 2021

Keywords: circular RNA, bioinformatics, alternative splicing, proliferation, triple negative breast
cancer
Copyright © 2021, Meagan P. Horton

DEDICATION
This thesis is dedicated to the people I cherish the most, and who have supported me
throughout the entirety of my scientific endeavors. My mother, who has always raised me to be
strong and independent by presenting herself first-hand as such. My brother, who could not be
more opposite of me in career interest, yet has been by my side nevertheless. My late father, whose
passing during my young teenage years fueled me to pursue the person I am today. Lastly, to the
future of female STEM, may your passion never fade.

ACKNOWLEDGEMENTS
I would like to thank my outstanding mentor and principle investigator, Dr. Margaret Park,
for her confidence in me as a young female scientist and her direct support and instruction as a
hands-on adviser. Having joined her laboratory as an undergraduate volunteer, she presented with
nothing but kindness and desire for me to learn and advance as a newly developing researcher. She
inspired me to delve deeper into my comprehensive scientific understanding, in addition to
captivating my love for wet-lab experimentation. I sincerely thank you for being nothing short of
compassionate, encouraging, and ultimately genuine; for pushing me to strive for excellence and
providing incredible leadership along the way.
My deepest gratitude extends to my mentor and former boss, Dr. Charles Chalfant, for his
willingness to invest in my career as an emerging researcher and his persistence in urging me to
be the dedicated scientist I am today. Allowing me to serve as a laboratory assistant in his
laboratory while volunteering in Dr. Park’s, instead of permitting me to endure a job in the service
industry to maintain my undergraduate livelihood, he demonstrated his devotion in progressing
me as an upcoming woman in STEM research. I thank you from the bottom of my heart for your
generosity and assurance in me.
Furthermore, I would like to thank my committee members (current and former), Dr.
Florian Karreth, Dr. Sandy Westerheide and Dr. Kristina Schmidt, for investing in my future and
making time to listen and provide feedback. Without their guidance, I would have less of an
understanding in molecular biology technique and experimentation, and limited perfection in
scientific presentation skills.

Throughout my opportunities in the labs of Dr. Park and Dr. Chalfant, I often looked to my
peers and senior scientists for advice. Without the help of my lab mates, Emily Mayo and Shaun
Stevens, experimentation likely would have been much more challenging and stress-ridden. I
deeply appreciate their guidance and mentorship. More so, I profoundly thank Dr. Christina Moss,
who took kindly to me as an undergraduate student in the genetics lab she was my graduate TA
for. Her certainty in me as a rising female scientist has been one of the top motivators in getting
me to where I am today. I thank her for taking many hours establishing my “lab hands” as well as
inspiring me to understand computational biology on levels I never wanted to.

TABLE OF CONTENTS
List of Figures

iii

List of Tables

iv

Abstract

v

Chapter One: Introduction
Triple-Negative Breast Cancer (TNBC)
Alternative Splicing
Non-coding RNAs (ncRNAs)
Circular Non-coding RNA
Circular RNAs in Cancer
Clinical Relevance
Hypothesis
Research Aims
Figures

1
1
2
3
4
4
5
5
6
6

Chapter Two: Bioinformatics
Abstract
Introduction
Materials and Methods
Cell Lines and Media
RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR)
Sequencing
Bioinformatic Analysis
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Results
CircRNA Target Prediction via Circtools
Validation of Selected CircRNAs
Discussion
Workflow & Target Prediction
Targets & Expected Expression
Validation & Rejection of Target Expression
Figures
Tables
Chapter Three: CircREV1 in TNBC

8
8
8
10
10
11
11
11
12
12
13
13
14
14
14
15
16
19
20

i

Abstract
Introduction
Materials and Methods
Cancer Cell Lines and Media
RNAi Design & Transfection

20
20
22
22
22

RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR)
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Proliferation Assay
Clonogenic Assay
Scratch Assay
Actin Cytoskeleton Focal Adhesion Assay
Results
Biological Assays
Discussion
CircREV1 Knockdown
Linear REV1 Knockdown
Proliferation After circREV1 Knockdown
Clonogenics After circREV1 Knockdown
Scratch Assay After circREV1 Knockdown
Actin Cytoskeleton / Focal Adhesion Assay After circREV1 Knockdown
Conclusions
Figures
Tables

23
23
24
24
24
25
25
25
26
26
26
27
28
29
30
30
31
34

References

35

Appendices
Appendix A: List of Cell Lines Used
Appendix B: List of siRNAs Used
Appendix C: Supplemental Figures & Tables
Appendix D: Unpursued Data

37
37
37
38
39

ii

LIST OF FIGURES
Figure 1: Alternative Splicing Yields RNA and Protein Diversity

6

Figure 2: CircRNA Production via Back-Splicing

7

Figure 3: Target Identification Workflow via Bioinformatics

16

Figure 4: Circtools-generated Expression Expectations for Selected Targets

17

Figure 5: In Vitro Expression Levels via qRT-PCR for Selected Targets

18

Figure 6: Knockdown of circREV1 via qRT-PCR

31

Figure 7: Proliferation Assays

31

Figure 8: Clonogenic Assays

32

Figure 9: Scratch Assay

32

Figure 10: Actin Cytoskeleton / Focal Adhesion Assays

33

Supplemental Figure A1: Differential Exon Usage of REV1 (ENSG00000135945)

40

Unpursued Data Figure B1: Alternative Splicing PCR of ST7

42

Unpursued Data Figure B2: Alternative Splicing PCR of OFD1

42

Unpursued Data Figure B3: CircPCMTD1 qRT-PCR

43

Unpursued Data Figure B4: Western Blots and Antibodies for circREV1

43

Unpursued Data Figure B5: MCF10A Proliferation Assay

44

Unpursued Data Figure B6: MCF10A Clonogenic Assay

44

Unpursued Data Figure B7: Linear REV1 Knockdown

45

iii

LIST OF TABLES
Table 1: Circtools-generated Targets

19

Table 2: Circtools-generated Primers for Selected Targets

19

Table 3: siRNAs Used

34

Supplemental Table A1: Explored Reference Genes

41

Supplemental Table A2: Reference Gene Primers

41

iv

ABSTRACT
Triple-negative breast cancer (TNBC) comprises only 24% of breast cancer cases, yet is
the second leading cause of cancer mortality in women due to its aggressive nature (1). This
increase in mortality is due to the lack of receptors for three targetable growth factors (HER2,
progesterone, and estrogen receptors). Our previous studies have indicated that these cancers are
highly dysregulated in respect to alternative splicing. Hence, we undertook a study aimed at
identifying circular RNAs (circRNAs) generated from back-splicing events which were
dysregulated in TNBC. We have identified a novel circRNA transcript, circular REV1 (circREV1),
which is upregulated in our TNBC cell lines. Its overexpression may be an indicator of TNBC and
its progression. The complexes formed between circRNAs and proteins or other RNA transcripts
are able to dysregulate gene expression, which is one of the hallmarks of cancer (2).
Next generation sequencing of RNA collected from breast epithelium and TNBC cell lines
were aligned with STAR aligner and bioinformatically analyzed for differential expression of
circRNAs via circtools (3). CircREV1 was found to be overexpressed in two TNBC cell lines,
while demonstrating minimal expression in breast epithelial cells. Quantitative polymerase chain
reaction (qRT-PCR) analysis, following reverse transcription of RNA collected from relevant cell
lines, validated these findings in vitro. Treatment with RNase R, to remove the linear construct of
REV1, confirmed that the circular isoform is responsible for the overexpression found in the
TNBC cell lines. The isoform we have honed in on is that of exon 3 back-spliced to exon 2, with
the intron spanning the two being retained.

v

Linear REV1 is suggested to function as a scaffolding protein to recruit DNA polymerases
for translesion synthesis in DNA repair mechanisms (4). It can be hypothesized that cancer may
manipulate this gene to facilitate bypass of cell cycle regulation machinery. While minimal data
has been published on the function of circREV1, it is predicted to be involved in a pathway which
favors cancer advancement. Ultimately, our findings suggest that circREV1 upregulation may be
influential in the transformation from breast epithelium to a more aggressive phenotype.
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CHAPTER ONE: INTRODUCTION
Triple-Negative Breast Cancer (TNBC)
Breast cancer is a commonly occurring disease that affects many individuals, specifically
women of all races and nationalities. While approximately 1 in 8 American women develop
invasive breast cancer in their lifetime, it more rarely occurs in men with an expectation of 2,650
diagnoses in 2021 (5). Advancements in research and treatments have decreased death rates, in
more recent years, in women over 50 years of age by 1% per year (5). However, breast cancer still
remains to be the second leading cause of cancer deaths in women behind lung cancer (the leading
cause of cancer deaths for men and women) (5). The severity of breast cancer increases when it is
classified as Triple-Negative Breast Cancer (TNBC). This class of breast cancer accounts for
around 10-15% of all breast cancers and is characterized by the lack of receptors for estrogen and
progesterone, in addition to non-overexpression of the protein HER2 (6). TNBC tends to respond
well to initial treatment administration, yet cancer cells that have escaped treatment make for a
very aggressive disease that grows and spreads with haste. Unfortunately, without the major
receptors and HER2 overexpression, there are limited options for targeted treatment, as the cancer
tends to be resistant, making for a poor prognosis.
Survival statistics for different types of cancer are generated by data keeping, which is
maintained by institutions, such as the National Cancer Institute (NCI). Specifically, the American
Cancer Society relies on the SEER database from the NCI, which does not group cancers by stages,
but rather groups them into classifications of them being localized (not spread outside the breast),
regional (spread to nearby structures/lymph nodes), and distant (spread to distant structures) (6).
1

Five year survival rates for TNBC that are localized happens to be a promising 91%, however, it
drops to 65% for regional diagnoses, and a mere 12% for distant diagnoses (6). Something to keep
in mind is that these numbers are not static, and do not take all factors in to consideration – each
tumor responds to treatment differently, each has their own grade, and each has a specified extent
to which it has spread.
While invasive breast cancers have various treatment options, TNBC has fewer options
due to the deficiency in receptors. These shortcomings mean that hormone therapies and drugs
targeting such are inadequate for an efficient treatment regime (6). Because surgery is an option
for those who have localized tumors, this lends to the higher survival rates seen for these
classifications. Oftentimes, chemotherapy can be administered prior to surgery in order to shrink
tumors on the larger end of the spectrum, and it can also be given after surgery in order to safeguard
and reduce chances of the tumor returning (6). Radiation is another option, but it does depend on
specific aspects of the tumor, such as how regional metastases are and what actions have been
taken prior to radiation (24). For more advanced diagnoses, other molecular mechanisms must be
employed, such as PARP inhibitors, progressive chemotherapies, and immunotherapy (6).

Alternative Splicing
The idea that humans create a multitude of different proteins using a set number of genes
is only possible due to the occurrence of alternative splicing. DNA contains regions that are protein
coding, called exons, and they are interspersed with regions that do not code for proteins, called
introns. Alternative splicing is the “cutting” of precursor mRNA, in which intronic sequences are
spliced out and exonic sequences are joined, producing different transcripts that go on to be
translated into different proteins. The precursor mRNA for one specific gene can give rise to many
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different proteins due to the inclusion or exclusion of different exons, promoting protein diversity.
When exons are ligated in the order in which they appear in a gene, this is called constitutive
splicing, while alternative splicing occurs when there is a diversion in such splicing, such as a
skipping of exons (7). Ultimately, alternative splicing is the explanation for the inconsistency
observed when it is seen that humans have approximately 25,000 protein coding genes, yet more
than 90,000 different possible proteins generated (7). The idea that alternative splicing yields more
proteins than the number of genes present in the human genome is visualized in Figure 1.

Non-coding RNA (ncRNA)
Non-coding RNA stems from transcribed messenger RNA from the DNA template, yet it
does not go on to be translated into protein. This provides reasoning for the term “non-coding,” as
it does not code for functional proteins. However, just because these RNAs do not encode for
functional proteins, it does not mean that they are not functional. These RNAs make up regulatory
factors involved in many cellular functions, such as transfer RNAs (tRNAs) in translation and
small nuclear RNAs (snRNAs) involved in splicing (8,19). In more recent years, many regulatory
non-coding RNAs have been discovered, such as piwi-associated RNAs, endogenous shortinterfering RNAs and microRNAs (miRNAs); these act as major regulators of gene expression
through a multitude of different pathways (8,19). The discovery of ncRNAs has been pivotal in
the field of gene research. Small interfering RNAs (siRNAs) can be utilized to study gene
expression due to their silencing abilities, and even extends further to aspects of disease
development where the roles of specific ncRNAs can be determined by the use of factors like
specifically designed siRNAs. NcRNAs must hold a significant amount of importance considering
they account for approximately 95% of the total RNA transcribed from the genome (9).

3

Circular Non-coding RNA
When considering alternative splicing and ncRNAs, one of the current areas of focus are
circular RNAs (circRNAs). CircRNAs are formed from an alternative splicing event called backsplicing, where an upstream 3’ splice site is joined to a downstream 5’ splice site, as depicted in
Figure 2 (21). Though circRNAs were initially discovered in 1976 and considered conserved
byproducts of splicing in low abundance and unknown function, biotechnology has allowed for
the identification of a large number of these molecules that tend to be expressed in a tissue- and
developmental-specific manner (9). Not much is known about their functions, but those that have
been characterized seem to act as miRNA sponges, preventing specific mRNA translation. Further
research has demonstrated that circRNAs may heavily influence gene expression via transcription
and RNA-binding protein (RBP) interactions. In addition to the fact that circRNAs are quite stable
due to their non-exposed 3’ and 5’ ends, their suspected roles make them an attractive target in
disease prevention and progression interference.

Circular RNAs in Cancer
CircRNA expression has shown correlation with many human diseases. Specifically, they
have been associated with autophagy, apoptosis, cell cycle, and proliferation, while further studies
have shown them to hold regulatory functions in diseases such as Parkinson’s and Alzheimer’s
(neurological), cardiovascular implications, and a number of cancerous tumors (9). For breast
cancer itself, one circRNA, circFoxo3, has been extensively studied, revealing its non-coding roles
in the inhibition of tumor growth and angiogenesis (9, 10). Upon inducing expression of circFoxo3,
TNBC cell line MDA231 displayed slowed proliferation and lessened cell survival when
undergoing H2O2 treatment (10). These researchers also undertook mice studies to understand the
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tumor formation with induced circFoxo3 expression and found that much smaller tumors formed
in mice injected with cells having upregulated expression (10). This study further displayed the
possibility of circRNAs acting as miRNA sponges by confirming circFoxo3’s interactions with
the miRNAs found to bind the Foxo3 host gene, as the host gene was more readily expressed due
to the lessened silencing by the miRNAs (10). It is clear that circRNAs function for regulatory
purposes, which cancer can exploit to its advantage, especially in terms of growth.

Clinical Relevance
Being the second leading cause of cancer deaths in the country, breast cancer has a high
incidence affecting nearly 1 in 8, or 13%, of the female U.S. population. Of these cases, 10-15%
of them are TNBC, leaving these individuals susceptible to a fast-progressing disease with an illperfected treatment plan. Because TNBC is so aggressive and fast growing in nature, in addition
to its limited treatment options and resistance to those available, it is highly important to determine
a more effective and targeted treatment regime for this subclass of breast cancer.

Hypothesis
Circular RNAs are a ncRNA molecule that hold regulatory roles in breast cancer and go
on to interact in manners that promote or inhibit cancer progression. The upregulation of circREV1
in TNBC cell lines compared to immortalized breast epithelial cells promotes the cancerous nature
of TNBC.

5

Research Aims
1) Identify circRNAs with dysregulated expression in triple-negative breast cancer via use of
bioinformatic analysis.
2) Determine if circREV1 expression affects cancer-related phenotypic changes.

Figures

Figure 1: Alternative Splicing Yields RNA and Protein Diversity
Alternative splicing produces RNA diversity and permits the production of nearly 150,000
proteins from only ~25,000 genes in the human genome.
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Figure 2: CircRNA Production via Back-Splicing
Back-splicing generates circRNAs by joining an upstream 3’ splice site to a downstream 5’ splice
site.
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CHAPTER TWO: BIOINFORMATICS
Abstract
Breast cancer is the second leading cause of cancer deaths in women. Not only is it
expected to be diagnosed in over 280,000 U.S. women in 2021, it is also expected to affect over
2,600 men this same year (5). Patients with TNBC face hardships when it comes to the available
treatment options, and due to its lack in identified targets and tenacity in progression, it has a poor
prognosis. Therefore, developing biotechnological methods are commonly employed to identify
molecular drivers that can serve as potential therapeutic targets. Bioinformatic analysis of total
RNA sequencing of TNBC samples serves as a starting point for nucleic acid targeting. Rising
attention on circRNAs presents bioinformatics as a major determinizing tool for unidentified
circRNAs that might be playing a larger role in the drive of TNBC than realized.

Introduction
Over 30% of newly diagnosed cancers in women will be breast cancers in 2021, and for
the same year 43,000 women in the U.S. alone are expected to pass away from it (5). While studies
for the causes and predispositions for breast cancers have allowed for physicians to better
recognize what permits these cancers to arise and progress, the treatment options are only so
plentiful. The number of effective treatment options critically declines when the classification of
the breast cancer happens to fall in the TNBC category, hence the emphasis for the identification
of unknown molecular drivers.
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In general, the field of bioinformatics involves the joining of molecular biology and
genetics with computer sciences focusing on mathematics and statistics (11). Bioinformatics
allows one to analyze large data sets that require intensive computational power to make the best
possible predictions for such data. Overall, it can involve collecting computational data from
biological data, building a computational model, solving problems with the modeling, and
testing/evaluating the computational algorithm (11). Most useful for potential target identification
is sequence analysis to gain an idea as to the ultimate function of genes and why they are expressed
in certain patterns.
Sequence analysis for the goal of obtaining RNA targets involves a series of steps for
optimal predictions. Transcriptomics focus on the complete set of RNA transcripts at a specific
time under specific conditions (20). For transcriptome analysis, RNA is harvested and selected for
in a manner that permits the non-polyadenylated transcripts to be present – in other words,
selection of protein coding RNAs containing a poly(A) tail is not the route to take. Instead, rRNA
is depleted from the total RNA samples, leaving behind ncRNAs and regulatory RNAs (12, 20).
At this point, cDNA is generated from the available RNA to be sequenced, which then goes on to
be analyzed bioinformatically. The sequenced material is aligned to a reference genome, then the
present transcripts are assembled for desired analysis.
Analysis of transcriptome-level sequencing includes identification of differential gene
expression and exon usage, alternative splicing, and even circular RNAs. Considering the
canonical splicing methods, where introns are spliced out and exons are joined, only one protein
per gene would be possible. However, there are alternative splicing methods that allow for
thousands of proteins to be produced per gene, meaning there are thousands of RNAs made for
one gene. Conclusively, alternative splicing creates a highly diverse set of RNAs, and they can be
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characterized further when considering the different mechanisms of alternative splicing. One
category of alternative splicing is back-splicing for the purpose of circRNA production. When an
upstream 3’ end is spliced to a downstream 5’ end, this is called back-splicing. This kind of splicing
allows for an exon that occurs later in the gene to be joined to an exon earlier in the gene, and often
results in the retention of intronic sequence spanning such exons, as displayed in Figure 2.
Exploitation of this alternative splicing pattern presents the potential identification of dysregulated
expression of these RNA species. We hypothesize that circRNAs have dysregulated expression in
TNBC cells when compared to immortalized breast epithelial cells, playing key roles in tumor
development and progression.

Materials and Methods
Cell Lines and Media
There were three TNBC cell lines used: MDA231, MDA468, and BT549. The
immortalized breast epithelium utilized was MCF10A. These cells were purchased from American
Type Culture Collection (ATCC) and cultured in either RPMI (TNBC lines; Gibco) or DMEM/F12
(immortalized breast epithelium; Lonza) media. The RPMI media has additives of 10% fetal
bovine serum (FBS: Gibco) and 1% penicillin/streptomysin (Gibco), while the DMEM/F12 media
was supplemented with 5% Horse Serum (Gibco) and fresh add-ins of 1000X epidermal growth
factor, hydrocortisone, and insulin. Cell lines were maintained in an incubator at 37C with 5%
CO2 at less than 90% confluency. Any experiments were performed within the first 15 passages.
Prior to harvesting cells for experiments using the pellets, they were rested in serum- and
antibiotic-free RPMI for 24 hours, thus reducing the differential effects of serum growth factors
on expression.
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RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA isolation was completed using the Quick-RNA Miniprep Kit (Zymo Research)
and purified when necessary using the RNA Clean & Concentrator (Zymo Research) following
manufacturer’s protocol. RT-PCR was performed using a high-capacity cDNA reverse
transcription kit following the manufacturer’s protocol with indication for use of RNase Inhibitor
(Applied Biosystems – Thermo Fisher Scientific).

Sequencing
MDA231 and BT549 TNBC RNA, as well as MCF10A breast epithelial RNA were sent to
the DNA Sequencing center at Brigham Young University for deep RNA-Seq. Prior to sequencing,
library preparation includes use of Ribo-Zero Gold (Illumina) to remove rRNA. Illumina HiSeq
2500 was used for 2 x 150 base pair paired-end sequencing to a depth of 100 million reads per
sample at minimum.

Bioinformatic Analysis
Before beginning analysis of the sequencing, raw read files were checked for quality using
FastQC (13). With Hg38 as the reference genome (GENCODE 27, Ensembl 91), sequencing was
aligned using STAR (chosen for the chimeric junction output) and assembled with Stringtie (14,
15, 16, 17, 22). Following alignment and assembly, circtools was then employed to produce raw
counts for detected circRNAs through exploitation of reads covering back-splice junctions with
subsequent analysis to limit predictions. Targets were ultimately identified using a q-value of <.05.
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Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Custom primers designed via circtools, and in table 2, were used for qRT-PCR. PowerUp
SYBR green master mix was utilized according to the guidelines in the user manual (ThermoFisher
Scientific). QRT-PCR was run with cDNA generated as described in the RT-PCR section (after it
was treated with RNase R to remove linear constructs), generally without the melting curve. Due
to variations in  actin levels across the utilized cell lines, another housekeeping gene was selected,
which was MRPL19 (Supplemental Table 1). Relative mRNA expression was normalized to
MRPL19 using the CT method.

Results
The workflow shown in Figure 3 was used to generate circRNAs targets from TNBCderived RNA-Seq data. Two TNBC cell lines, MDA231 and BT549, and one immortalized basal
epithelial cell line, MCF10A, were used in the bioinformatic prediction study. These three cell
lines, in addition to another TNBC cell line, MDA468, were utilized for in vitro expression
validation. Mammary basal epithelial cells, MCF10A, were used as the control non-cancerous cell
line that express breast-specific antigens. MDA231, BT549, and MDA468 cell lines represent
TNBC cell lines, each with their own specifications. MDA231 cells are adenocarcinoma-derived
mammary epithelial cells with multiple mutations yielding them nearly triploid in chromosome
count with two deletions and 11 stable rearrangements. BT549 cells are ductal carcinoma-derived
mammary epithelial cells with multiple mutations yielding them a hypertriploid chromosome
count with abnormal X chromosomes, 5 chromosomal under-representations, 3 chromosomal
over-representations, and the presence of 4 marker chromosomes. MDA468 cells are
adenocarcinoma-derived mammary epithelial cells with multiple mutations yielding them a
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hypotriploid chromosome count with 7 under-representations due the presence of 19 marker
chromosomes.

CircRNA Target Prediction via Circtools
Utilizing the general parameters suggested for circtools analysis and a q-value of <.05,
there were 45 target predictions produced, as depicted in Table 1 (18). Of these 45 targets, seven
were manually picked for further investigation and are represented in Figure 4A-G. In addition to
literature on the host genes of the predicted targets, selection was based on a difference in log2 fold
change (approximately 3-fold change or more) between the mammary basal epithelial cells and
the two sequenced TNBC cell lines, MDA231 and BT549; if expression levels do not present this
kind of log2 fold change, they were selected due to an oddity like having no expression at all in
one line, or having heightened expression in one TNBC line and not the other while having similar
expression to one or the other in the immortalized mammary basal epithelium. Circtools-generated
graphs on the expression of these selected circRNA targets are represented in Figures 4A-G.

Validation of Selected CircRNAs
The predicted expression patterns of the seven hand-picked circRNA targets were validated
prior to pursuing any cancer-related phenotypic effects. Circtools has an option to generate primers
to directly detect the target in question. The primers utilized for qRT-PCR detection are depicted
in Table 2. It is important to note that RNA utilized for cDNA products were first treated with
RNase R to eliminate all linear constructs in order to ensure that any detection was due to only
circular isoforms. Expression levels in vitro are presented in Figure 5A-G.
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Discussion
Workflow & Target Prediction
Following the workflow presented in Figure 3, we were able to successfully utilize
bioinformatics to identify circRNA targets in TNBC for further investigation. As Figure 3 depicts,
we were able to take RNA-Seq data from TNBC and non-tumorigenic cell lines and align the
sequencing to the Hg38 genome using STAR Aligner, which was able to generate an output with
chimeric junction reads. RNA-Seq alignment output files were then be employed to assemble
potential transcripts in a bioinformatic program called Stringtie. Assembled transcripts were
analyzed in circtools to predict which circRNAs were present. This was possible due to the
chimeric junction read output via STAR Aligner. Circtools generated a table of potential targets,
which was further limited with desired specifications. We asserted a q-value of <.05, allowing us
to cap the predictions to 45 targets presented in Table 1. Of these 45 targets, seven were selected,
as depicted in Figure 4A-G, based on a difference in log2 fold change (approximately 3-fold change
or more) between the immortalized mammary basal mammary epithelial cells and the two
sequenced TNBC cell lines, MDA231 and BT549. Expression levels that did not present this kind
of log2 fold change were selected for further exploration due to an oddity, such as having no
expression in one line at all, or having heightened expression in one TNBC line and not the other
while having similar expression to one or the other in the immortalized mammary basal epithelium.

Targets & Expected Expression
In pursuing the seven selected targets for further investigation, we begin with validating
their expected expression levels prior to moving forward with experiments relative to them.
Expected expression levels, generated via circtools analysis, are presented in Figure 4A-G. In order
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to validate these expected expression levels, we utilize primers generated in circtools, listed in
Table 2, via qRT-PCR using PowerUp SYBR green master mix. Expression levels in their
respective cell lines are presented in Figure 5A-G.

Validation & Rejection of Target Expression
One circRNA was confirmed to express similarly to the circtools predictions, while the
other six did not. CircREV1 expression levels were validated to agree with the expected expression
levels from circtools, as seen in comparison of Figure 4A and Figure 5A. Expression levels for
this circRNA were checked multiple times with numerous cell pellets. CircSETD3 qRT-PCR
analysis did not agree with the circtools prediction, as seen in comparison between Figure 4B,
where TNBC cell lines show upregulated expression, and Figure 5B, where expression levels in
the TNBC lines show downregulation. CircZNF124 qRT-PCR analysis had large error bars in the
mammary basal epithelium samples, however, it did show the expected downregulation of
expression in the MDA231 TNBC cell line when compared to the non-cancerous line. Essentially,
the first confrontation of expression levels for this circRNA did agree when comparing Figures 4C
and 5C, however, they were not checked multiple times with numerous cell pellets and this target
was not further pursued for experiments. CircPARD3 qRT-PCR analysis did not agree with the
circtools prediction, as seen in comparison between Figure 4D, where TNBC cell lines show
upregulated expression, and Figure 5D, where expression levels in the TNBC lines show
downregulation. CircBARD1 qRT-PCR analysis did not agree with the circtools prediction, as
seen in comparison between Figure 4E, where TNBC cell lines show upregulated expression, and
Figure 5E, where expression levels in the TNBC lines show downregulation. CircLPAR1 qRTPCR had large error bars and skewed expression levels for both the MDA231 TNBC cell line as
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well as the non-cancerous MCF10A cell line. Taking these facts aside, when comparing the
expected expression levels in Figure 4F to the in vitro expression levels in Figure 5F, they did not
agree. The circtools expectations presented the non-cancerous MCF10A cell line as having
absolutely no expression, while this was not the case in our in vivo exploration. CircMGA qRTPCR analysis did not agree with the circtools prediction, as seen in comparison between Figure
4G, where TNBC cell lines show upregulated expression, and Figure 5G, where expression levels
in the TNBC lines show downregulation.

Figures

Figure 3: Target Identification Workflow via Bioinformatics
Bioinformatics-guided target selection of circRNAs detected within RNA-Seq of basal mammary
epithelial cells (MCF10As) and Triple-Negative Breast Cancer cell lines (MDA231 & BT549).
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Figure 4: Circtools-generated Expression Expectations for Selected Targets
Circtools-generated graphs of the selected targets from predicted targets of circRNAs. Names of
the linear host genes are as follows: A) REV1, B) SETD3, C) ZNF124, D) PARD3, E) BARD1,
F) LPAR1, G) MGA.
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Figure 5: In vitro Expression Levels via qRT-PCR for Selected Targets
QRT-PCR analysis of in vitro expression levels for the selected circRNA targets. The represented
circRNAs targeted are as follows: A) circREV1, B) circSETD3, C) circZNF124, D) circPARD3,
E) circBARD1, F) circLPAR1, G) circMGA. Targets in B-G were primarily checked in cell lines
MCF10A, MDA231 and MDA468, as BT549 cells were not cultured at that point in time, while
target A was validated in all four cell lines, MCF10A, MDA231, BT549, and MDA468.
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Tables
Table 1: Circtools-generated Targets
Circtools-generated targets using program-specified parameters and q-value of <.05 following
workflow presented in Figure 3.

Table 2: Circtools-generated Primers for Selected Targets
Circtools-generated primers for detection of the specific target prediction. These were utilized in
qRT-PCR for primary validation of expression patterns predicted in circtools.
Target
Forward Sequence
Reverse Sequence
circREV1
5’-CAT TTT CAG CTC GCT
5’-TCG ATC AGA TGC TGC
TCC TC-3’
TAT GC-3’
circSETD3
5’-CAC CAG TGC CAG ATT
5’-AAC ACA GCT CGA CAG
TCT GA-3’
TAC GC-3’
circZNF124
5’-TCA CAG CCA CAT CCT
5’-GAT GGG GTT TCA CCG
CAA AG-3’
TGT TA-3’
circPARD3
5’-CAT CTT TTC GAT GTT
5’-ACG AGA AGG GCA TAT
TGC CA-3’
GAT GG-3’
circBARD1
5’-TTC GAG GGC TAA ACC
5’-TAT GGA GCC TCC AGA
ACA TT-3’
AAT GC-3’
circLPAR1
5’-GTG GAT GGG GAG CTT
5’-TCT CGG CAT AGT TCT
CAT AA-3’
GGA CC-3’
circMGA
5’-AGA TAG GTG GAT GGG
5’-TTG TCT CCC GTA GTT CTG
GAG CT-3’
GG-3’
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CHAPTER THREE: CIRCREV1 IN TNBC
Abstract
Different forms of alternative splicing yield various RNA species that may then be
translated into protein, or may remain in RNA form and considered one of many ncRNAs. Backsplicing is an alternative splicing event where an upstream 3’ splice site is joined to a downstream
5’ splice site. This novel mechanism creates circRNAs where exons, or sometimes introns and
exons, are joined in a reverse fashion where the nucleic acid backbone is circular with no free ends.
CircRNAs have been found to play regulatory roles in human diseases, sometimes in manners
allowing them to promote or inhibit cancer progression. We have found evidence that circREV1
is upregulated in TNBC cell lines when compared to immortalized mammary basal mammary
epithelium. We further investigate the biological effects of circREV1 in order to determine if there
is a cancer-related phenotype. Biological assays evaluating the phenotypic effects of knocking
down the circREV1 transcript target we identified has revealed that inhibited expression of
circREV1 in established TNBC lines does limit the proliferation and colony formation as well as
its ability to close wounds. These findings suggest that circREV1 holds some kind of role in TNBC
that allows it to grow more aggressively.

Introduction
Breast cancer is the most commonly diagnosed cancer amongst women in the U.S., as 1 in
8 women will develop an invasive form of it (5). Considering these cases, up to 15% of them will
be TNBC (6). Because of TNBC’s lack in targetable factors, such as HER2 and receptors for
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progesterone and estrogen, this breast cancer subtype proves to be tenacious and difficult to treat.
There is a large demand to determine new targets for treatment in this cancer, as the survival rates
plummet with increasing distance in how far it spreads.
One field that presents a more promising outlook for targetable factors is that of ncRNA.
These RNAs make up regulatory factors involved in many cellular functions and, in more recent
years, have been discovered to act as major regulators of gene expression through a multitude of
different pathways (8, 19). NcRNAs can be manipulated to characterize their effects on gene
expression, and further offers aspects to better understand disease development. Considering they
account for up to 95% of the total RNA transcribed from the genome, it is likely that ncRNAs hold
significant roles yet to be defined (9).
Rising in ncRNA focus are circRNAs, especially in the aspect of human disease.
Biotechnology allows for the identification of a large number of these molecules that tend to be
expressed in a tissue- and developmental-specific manner (9). Little has been solidified in relation
to their functions, but circRNAs that have been characterized act as miRNA sponges, preventing
mRNA translation. They also present heavy influence on gene expression via transcription and
RNA-binding protein (RBP) interactions (9). The suspected roles of these circRNAs make them a
prospective target in disease prevention and progression interference.
CircRNAs are associated with autophagy, apoptosis, cell cycle, and proliferation, while
other studies describe their regulatory functions in diseases such as Parkinson’s and Alzheimer’s
(neurological), cardiovascular diseases, and a number of cancer typess (9). Through bioinformatic
analysis, we identified a novel circRNA, circREV1, which is upregulated in TNBC cell lines when
compared to immortalized mammary basal epithelium. CircREV1 is on the minus (-) strand of
chromosome 2, with exon 3 back-spliced to exon 2 and contains the intron spanning the two. We
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hypothesize that circREV1 may influence phenotypes which may affect cell proliferation and
motility, two hallmarks of transformation.

Materials and Methods
Cancer Cell Lines and Media
There were three TNBC cell lines used: MDA231, MDA468, and BT549. The
immortalized breast epithelium utilized was MCF10A. These cells were purchased from American
Type Culture Collection (ATCC) and cultured in either RPMI (TNBC lines; Gibco) or DMEM/F12
(immortalized breast epithelium; Lonza) media. The RPMI media has additives of 10% fetal
bovine serum (FBS: Gibco) and 1% penicillin/streptomysin (Gibco), while the DMEM/F12 media
was supplemented with 5% Horse Serum (Gibco) and fresh add-ins of 1000X epidermal growth
factor, hydrocortisone, and insulin. Cell lines were maintained in an incubator at 37C with 5%
CO2 at less than 90% confluency. Any experiments were performed within the first 15 passages.
Prior to harvesting cells for experiments using the pellets, they were rested in serum- and
antibiotic-free RPMI for 24 hours, thus reducing the differential effects of serum growth factors
on expression.

RNAi Design & Transfection
In order to silence the circREV1 transcript, siRNA was designed using Integrated DNA
Technologies (IDT) to cover the back-splice junction. The sequence for this siRNA was:
3’GUUAAUGGAUACACAGAAGUU’5. For the negative control siRNA treatment, Negative
Control No.1 from Ambion was used (AM4611). In the case of knocking down the linear construct
of REV1, pre-designed and target-confirmed siRNA from Ambion was employed (AM16704).

22

CircREV1 was successfully knocked down without off-target effects at a concentration of 75 nm,
while the negative control was generally administered at a concentration of 50nm. When trying to
knockdown the linear construct, the cells do not handle this well, undergoing visual cell death at
concentrations anywhere from 50-200nm with increasing effects at higher concentrations.
Transfections were administered using Dharmafect 4 in MDA231 cells (and Dharmafect 1 in
MCF10A when attempted) according to the manufacturer’s protocol and suspended in complete
medium. When harvesting cells, they were taken at 72 hours post-transfection.

RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA isolation was completed using the Quick-RNA Miniprep Kit (Zymo Research)
and purified when necessary using the RNA Clean & Concentrator (Zymo Research) following
manufacturer’s protocol. RT-PCR was performed using a high-capacity cDNA reverse
transcription kit following the manufacturer’s protocol with indication for use of RNase Inhibitor
(Applied Biosystems – Thermo Fisher Scientific).

Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Custom primers designed via circtools, and in Table 2 were used for qRT-PCR. PowerUp
SYBR green master mix was utilized according to the guidelines in the user manual (ThermoFisher
Scientific). QRT-PCR was run with cDNA generated as described in the RT-PCR section (after it
was treated with RNase R to remove linear constructs), generally without the melting curve. Due
to variations in  actin levels across the utilized cell lines, another housekeeping gene was selected,
which was MRPL19. Relative mRNA expression was normalized to MRPL19 using the CT
method. Any time linear REV1 was assessed in qRT-PCR, IDT PrimeTime Primer
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Hs.PT.58.14530085 was utilized, while the primer indicated in Supplemental Table 2 was
employed for MRPL19.

Proliferation Assay
Cells were plated onto 96-well plates at 2.5x103 cells per well. WST-1 assay (SigmaAldrich) was completed according to the manufacturer’s protocol. WST-1 dye was added,
incubated at 37C with 5% CO2 for 30-45 minutes, and absorbance was measured on a BioTek
Synergy 2 plate reader on alternating days 0-6 at 440 nm.

Clonogenic Assay
Clonogenic assays were performed by plating 250 cells per well on a 6-well plate. Media
was changed every 3-4 days and colonies were monitored to avoid overgrowth, while ensuring
colonies had at least approximately 50 cells (as a cell colony is generally defined to consist of).
Cells were fixed with 10% formalin 9-14 days after seeding and stained with crystal violet prior
to counting of colonies. (23)

Scratch Assay
Scratch assays were seeded at a concentration of 3x105 cells per well on a 24-well plate
and settled to 100% confluency to create a monolayer of cells. Prior to inducing a scratch down
the middle of the well, cells were serum-starved with media consisting of only 2% FBS for 3 hours.
Upon serum-starvation, a scratch was carefully induced with a sterile P20 pipette tip, rinsed with
PBS, and serum-starving media replaced. The plate was then placed in a Keyence Microscope
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fitted for live cell imaging meeting the tissue culture conditions previously described. Images were
taken every 5 minutes for 24 hours after setting points for images to be taken at for each well.

Actin Cytoskeleton Focal Adhesion Assay
Cells were plated on a 4-well chamber plate at a concentration of 1.25x105 cells per well.
Prior to fixation and staining, wells were scratched twice with a sterile P20 pipette tip, dividing
the well into 3 sections, then rinsed with PBS. Fixation and staining were completed according to
the manufacturer’s protocol in the kit for the actin cytoskeleton / focal adhesion staining (SigmaAldrich).

Results
With validation of the circtools-generated predictions of expression levels in the relative
cell lines, knockdown experiments were undertaken to determine how lack in expression of
circREV1 affects TNBC cell lines. Cells were harvested 72 hours after the knockdowns to
determine, via qRT-PCR, that knockdown was achieved; these qRT-PCR analyses are represented
in Figure 6A-C.

Biological Assays
To determine the effects of circREV1 knockdown, biological assays were plated the
morning following the afternoon of transfection. WST-1 proliferation assays to measure how
quickly the cells replicate are represented in Figure 7A-C. We then evaluated the ability for colony
formation on a plate via clonogenic assays, presented in Figure 8A-C. Further, we wished to assess
cell motility via the scratch assay, represented in Figure 9. An attempt to view differences in cell
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morphology, motility, and polarity in actin cytoskeleton / focal adhesion staining is portrayed in
Figure 10. With approximately 4-fold change in circREV1 expression following circREV1
knockdown, there are significant changes in proliferation, clonogenics, and wound healing. Our
results suggest that limited circREV1 expression lends to weakened proliferation and colony
formation, as well as hindered ability to close a wound.

Discussion
CircREV1 Knockdown
After successful validation of the circtools-expected expression levels of circREV1in vitro,
we began to determine the effects of knocking down its expression via siRNA. Figure 6A
represents the qRT-PCR of the optimized knockdown in TNBC cell line, MDA231. It is shown
that significant knockdown was achieved with limited off-target affects to the linear host gene.
Using the same approach to accomplish knockdown in MDA231, circREV1 expression was
limited in BT549, as seen in Figure 6B. It was also determined that nearly no off-target affects to
the linear host gene were seen with circREV1 knockdown. With the same regime for circREV1
knockdown in MDA468, there was slightly more knockdown than seen in BT549, yet slightly
more off-target effects than seen with BT549, depicted in Figure 6C. It was determined that 75 nm
was the optimal concentration to knockdown circREV1 without significantly affecting the linear
host gene.

Linear REV1 Knockdown
Linear knockdown was inconsistent and often lead to considerable cell death, making it
hard to harvest cells for qRT-PCR analysis. Because of the complications seen with linear REV1
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knockdown, it was decided that experiments involving their knockdown may be unreliable and
were not further pursued. The minimal qPCR analysis that was able to be completed is represented
in Unpursued Data Figure 7A-C. While these experiments were not further explored, their
proliferation and clonogenic data collection for TNBC cell lines BT549 and MDA468 are included
in their respective graphs (Figures 7B-C & 8B-C) due to being ran during same exact time as the
relative experiments for the circREV1 knockdown in these cell lines. Linear knockdown was not
initially taken into account when completing biological assays in the MDA231 TNBC cell line. It
was determined that knocking down the linear host gene was too lethal for TNBC cells, as they
may be relying on the REV1 protein to bypass abasic lesions during the cell cycle, as that has been
suggested as its major role.

Proliferation After circREV1 Knockdown
Without circREV1 expression, proliferation of TNBC cells was significantly hindered. As
seen in Figure 7A-C, absorbance at 440 nm was much less in cells with circREV1 knockdown for
all TNBC cell lines, MDA231, BT549, and MDA468. It is likely that circREV1 is responsible for
binding miRNAs or RBPs that are involved during the cell cycle by recognizing mishaps and
mutations. With these suspected interactions, circREV1 binding to such would normally prohibit
their interactions to step in and ensure the cell does not replicate and undergoes apoptosis, thus
their knocked down expression would lend to lessened proliferation.
Linear REV1 knockdown was also read for TNBC cell lines BT549 and MDA468, shown
in Figure 7B-C; it was not considered during the proliferation assay for MDA231. These figures
do show that there was a significant reduction in proliferation for MDA468, however, the
knockdown for linear REV1 appeared to be much more lethal for this cell line in particular.
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However, the BT549 cell line indicated that the proliferation was able to bounce back. This could
be due to the presence of different mutations in the different cell lines, making it possible for one
cell to overcome the inconvenience and not the other, as cell signaling reliance seemed to be much
heavier in the MDA468. In every attempt to knockdown linear REV1 for the MDA468 cell line,
there was a visual abundance of cell death. Linear knockdown was inconsistent and often lead to
considerable cell death, making it hard to harvest cells for qRT-PCR analysis. Because of the
complications seen with linear REV1 knockdown, it was decided that experiments involving their
knockdown may be unreliable and are therefore not further pursued.

Clonogenics After circREV1 Knockdown
Following knockdown of circREV1 expression, the ability of TNBC cells to form colonies
from a single cell was significantly reduced. As seen in Figure 8A-B, the number of colony forming
units was much less in cells with circREV1 knockdown for two TNBC cell lines, MDA231 and
BT549. There was no significance found for the lesser number of colonies formed for the MDA468
cell line following circREV1 knockdown. While the knockdown was of significance in this cell
line, this could be due to the nature of these cells, as they always present heavy reliance on
signaling from nearby cells for growth in general tissue culture and possibly increase growth
signaling due to the low abundance of cells present. The lessened colony formation following
circREV1 knockdown in MDA231 and BT549 is likely due to the suspected responsibility of
circREV1 binding miRNAs or RBPs involved during the cell cycle by recognizing mishaps and
mutations. Suggesting these interactions means that circREV1 expression would normally
promote binding to prohibit cell cycle precautions from stepping in and ensuring the cell does not
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replicate and undergoes apoptosis, thus its knocked down expression would lend to limited colony
formation
Linear REV1 knockdown was also considered for TNBC cell lines BT549 and MDA468,
shown in Figure 8B-C; it was not considered during the clonogenic assay for MDA231. These
figures show that there was not a significant difference in the number of colony forming units for
these two cell lines. In general, these two cell lines do not handle the knockdown of linear REV1
very well, especially the MDA468 cell line as it displays a visual abundance of cell death. Because
of this, it is likely that these cells only began forming colonies with the few cells that retained life
toward the end of this assay once the effective knockdown of linear REV1 began to wear off.
Linear knockdown was inconsistent and often lead to considerable cell death, making it hard to
harvest cells for qRT-PCR analysis. Because of the complications seen with linear REV1
knockdown, it was decided that experiments involving their knockdown may be unreliable and are
therefore not further pursued.

Scratch Assay After circREV1 Knockdown
When considering how well TNBC cells close a wound after circREV1 knockdown, we
saw MDA231 TNBC cells close 27% less of the wound than the same cells having non-targeting
siRNA treatments. While each set of cells worked to close the wound over the 24 hour time-lapse,
much less closure was achieved with those enduring circREV1 knockdown, as seen in Figure 9.
Cell migration is known to play important roles in physiological and pathological development
and extends further to angiogenesis and tumor metastasis. The MDA231 TNBC line is said to be
the most aggressive of the three TNBC cell lines utilized, therefore one of the major goals of this
cell line is going to be inhabitance of “uncharted territory.” We likely see the reduced closure of
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the wound with circREV1 knockdown due to the stalling in cell cycle processes and confirmed
hindrance in proliferation. It has been noted in other studies that cell proliferation may bias this
kind of experiment due to its influence on scratch closure (25). When attempting this assay with
BT549 and MDA468 cells, neither cell line displayed a directed attempt to close the wound, they
rather grew without direction and cells moved around nonsensically.

Actin Cytoskeleton / Focal Adhesion Assay After circREV1 Knockdown
Figure 10 displays the actin cytoskeleton / focal adhesion assay with and without circREV1
knockdown. Unfortunately, the anti-vinculin supplied with the Sigma-Aldrich kit did not stain
these cells in a manner that emits visible fluorescence, no matter how high or low the exposure
concentration was. For MDA231, BT549, and MCF10A cell lines, there were not obvious
differences seen in cell morphology, as displayed in Figure 10 with the respective magnifications
denoted. The lack in visible differences may be due to unsuccessful anti-vinculin staining, but
more so could be due to the idea that circREV1 influences must not change cell morphology,
motility, or polarity.
Conclusions
Overall, circREV1 has been seen to play roles in proliferation, ability to form colonies, and
ability to close a wound in TNBC cells. Without circREV1 expression, all three TNBC cell lines
see a significant reduction in their proliferation over six days. For clonogenic assays, two of the
three TNBC cell lines display a significant decline in the number of colony forming units over a
9-14 day period. It is also seen that with muted circREV1 expression, MDA231 cells have limited
ability to close a wound like they do with normal expression levels. Ultimately, circREV1 may be
utilized as a means to promote TNBC cell cycle turnover or allowing the bypass of apoptotic
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machinery in cell cycle checkpoints. It is shown that circREV1 plays an important role in TNBC’s
viability and ability to grow at the rates it does.

Figures

Figure 6: Knockdown of circREV1 via qRT-PCR
qRT-PCR representing knockdown of circREV1, optimized to limit off-target affects to the linear
isoform, in: A) MDA231, B) BT549, and C) MDA468.

Figure 7: Proliferation Assays
WST-1 proliferation assay following circREV1 knockdown in: A) MDA231, B) BT549, and C)
MDA468. No linear knockdown is represented in the graph for MDA231 due to it not being
considered during the run for their biological assays.
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Figure 8: Clonogenic Assays
Clonogenic assays following circREV1 knockdown in: A) MDA231, B) BT549, and C) MDA468.
No linear knockdown is represented in the graph for MDA231 due to it not being considered during
the run for their biological assays.

Figure 9: Scratch Assay
Scratch assay with time points of 0 hours and 24 hours in MDA231 following knockdown of
circREV1. BT549 and MDA468 were not analyzed due to their lack in movement to close the
wound, as the cells in their two assays moved around with no real direction.
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Figure 10: Actin Cytoskeleton / Focal Adhesion Assays
Actin cytoskeleton / focal adhesion assays following circREV1 knockdown in MDA231 (60X),
BT549 (40X), and MCF10A (60X).
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Tables
Table 3: siRNAs Used
siRNAs utilized to knockdown their respective target in each cell line.
Target
Manufacturer
Negative Control

Ambion – Cat#: AM4611

circREV1

Dharmacon – Oligo ID: HORMK-000001
(GUUAAUGGAUACACAGAAGUU)
Ambion – Cat#: AM16704

Linear REV1
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Appendix A: List of Cell Lines Used

Cell Line

Cancer Type

ATCC Description

MCF10A

N/A

non-tumorigenic epithelial cell line derived
from mammary gland

BT549

TNBC

invasive ductal carcinoma from breast

MDA231

TNBC

adenocarcinoma from breast

MDA468

TNBC

metastatic adenocarcinoma from breast
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Appendix B: List of siRNAs Used

Target

Manufacturer

Negative Control

Ambion – Cat#: AM4611

CircREV1

Dharmacon – Oligo ID: HORMK-000001
(GUUAAUGGAUACACAGAAGUU)

Linear REV1

Ambion – Cat#: AM16704
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Appendix C: Supplemental Figures & Tables

Supplemental Figure A1: Differential Exon Usage of REV1 (ENSG00000135945)
Differential exon usage of REV1 in which “E056” represents Exon 2 and “E054” represents Exon
3. This is determined by the fact that our transcript is on the negative strand and corresponds to
exons 2 and 3 in the reverse transcript assembly. “Can” in red represents BT549, “Met” in blue
represents MDA231, and “NL” in green represents MCF10A.
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Supplemental Table A1: Explored Reference Genes
Representing the reasoning as to why MRPL19 was chosen as the reference gene for qRT-PCR
normalization. CT values represent the cycle (out of 40) at which the nucleic acid adequately
amplified. Reference genes need to amplify at approximately the same cycle in order to
appropriately normalize across each cell line. (-R) represents the idea that these cell pellets were
not treated with RNase R, and (cc) represents the idea that these cell pellets were run through an
RNA Clean & Concentrator Kit following RNA extraction.

Supplemental Table A2: Reference Gene Primers
qRT-PCR primers utilized to determine the best fit reference gene.
Target
RPLP0
MRPL19
Actin B
B2-MG

Manufacturer or Sequence
IDT PrimeTime: Hs.PT.39a.22214824
IDT PrimeTime: Hs.PT.58.40629433
IDT PrimeTime: Hs.PT.39a.22214847
F: 5’-AAC TTA GAG GTG GGG AGC AG-3’
R: 5’-CAC AAG CAT GCC TTA CTT TAT C-3’
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Appendix D: Unpursued Data

Unpursued Data Figure B1: Alternative Splicing PCR of ST7
Alternative splicing exploration of ST7 in the respective cell lines. The image represents a
polyacrylamide DNA gel with PCR run at 56 degrees Celsius for 28 cycles. Set 1 primers were to
target a product of 428 base pairs while Set 2 primers were to target a product of 533 base pairs.

Unpursued Data Figure B2: Alternative Splicing PCR of OFD1
Alternative splicing exploration of OFD1 in the respective cell lines. The image represents a
polyacrylamide DNA gel with PCR run at 56 degrees Celsius for 32 cycles. Set 1 primers were to
target a product of 501 base pairs while Set 2 primers were to target a product of 203 base pairs.
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Unpursued Data Figure B3: CircPCMTD1 qRT-PCR
QRT-PCR analysis of in vitro gene expression for circPCMTD1. According to the targets in Table
1, expression should have been upregulated in MDA231 compared to MCF10A.

Unpursued Data Figure B4: Western Blots and Antibodies for circREV1
Western Blot of MDA231 and MDA468 with circREV1 knockdown and linear REV1 knockdown.
REV1 protein is said to be approximately 132 kDa while actin is approximately 40 kDa. While
protein levels were nanodropped to ensure even loading, the actin levels seem to indicate that there
was still uneven loading concentrations. Experiments were not reproduced due to the lack in
available cells to plate for protein and RNA harvesting when running biological assays. Antibodies
utilized are represented in the table below the blots.
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Normalized Absorbance (440 nm)

MCF10A Proliferation- Run 1
2.5
2.0

*
***

1.5

NT
circKD
linKD

1.0
0.5
0.0
Day 0

Day 3

Unpursued Data Figure B5: MCF10A Proliferation Assay
Proliferation data for MCF10As following knockdown of circREV1 and linear REV1.
Unfortunately, a lab mate had to complete the Day 3 reading due to illness of the original
researcher, and they put the WST1 dye on all of the remaining plates, meaning the following days
were not able to be read. Experiments were not reproduced due to the lack in urgency to emphasize
the knockdown of circREV1 in the non-cancerous cell line.

Unpursued Data Figure B6: MCF10A Clonogenic Assay
Clonogenics data for MCF10As following knockdown of circREV1 and linear REV1. Colonies
for this cell line took very long to form and were also sparse. Experiments were not pursued or
reproduced due to the lack in urgency to emphasize the knockdown of circREV1 in the noncancerous cell line.
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Unpursued Data Figure B7: Linear REV1 Knockdown
Knockdown of linear REV1 in: A) MDA231, B) BT549, and C) MDA468. Linear knockdown was
inconsistent and often lead to considerable cell death, making it hard to harvest cells for qRT-PCR
analysis. Because of the complications seen with linear REV1 knockdown, it was decided that
experiments involving their knockdown may be unreliable and were therefore not further pursued.
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